THOMSON MEDICAL GROUP LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration No. 199908381D)

STRATEGIC PARTNERSHIP WITH PLANO PTE LTD

The Board of Directors of Thomson Medical Group Limited (the "**Company**" or "**TMG**", together with its subsidiaries, the "**Group**") wishes to announce that Thomson X Pte Ltd ("**TX**"), a wholly owned subsidiary of the Company have signed a strategic partnership agreement with Plano Pte Ltd ("**Plano**"), a Singapore-based HealthTech startup that promotes the use of innovative technology to provide a wide range of eye health and wellness solutions to address the global myopia burden in Singapore, the region and beyond.

Myopia is steadily growing into one of the biggest public health challenges in the world, affecting an estimated 2.6 billion people globally, or about one third of the world's population. By 2050, myopia is projected to affect 5 billion people, which is estimated to be about half of the world's population. Developed economies in Asia such as Singapore, Hong Kong, Taiwan and South Korea have reported myopia rates of more than 80% and the estimated direct annual costs of managing myopia globally amounts to US$320 billion.

Plano is a health technology company that specialises in myopia management through education and awareness, innovative technological solutions and AI. Supported by the Singapore National Eye Centre, Singapore Eye Research Institute, National Health Innovation Centre and Enterprise Singapore, together with its recent strategic alliance with Santen Pharmaceutical Co., Ltd., a global ophthalmic leader, Plano is a leading advocate in raising awareness and educating the public on myopia, its risk factors and management strategies.

Plano is the latest strategic partner to come on board the TX platform to deliver innovative health and wellness solutions globally. As part of the partnership, TX has been granted an option to subscribe for a minority equity stake in Plano. The option can be exercised in three tranches over a 6-year period subject to certain milestones and business performance. This allows TX to participate and be invested in the growth of Plano.

The partnership with Plano allows TX to be part of the fast-growing HealthTech startup ecosystem and helps to future-proof the Group's business model and growth by leveraging on technology and connectivity. Through this partnership, the Group's patients at Thomson Paediatric Clinic and Thomson Kids in Singapore, and Thomson Eye Centre in Malaysia will soon have access to Plano's innovative eye-care solutions on top of Thomson's existing healthcare services. In addition, the partnership will also accelerate Plano's market potential through TX's global partner, the Global Esports Federation, by delivering innovative eye health services to Esports athletes and gamers who are exposed to long screen time.

The proposed partnership is not expected to have any material impact on the net tangible assets per share and earnings per share of the Company for the financial year ending 30 June 2021.

Dr Wong Chiang Yin, the Executive Director and Group Chief Executive Officer of the Company and the Controlling Shareholder have a minority equity interest, either through their direct or indirect shareholding in Plano. Dr Wong and Mr Lim Wee Kiat, an associate of the Controlling Shareholder, have abstained from participation in the Board decision on the partnership agreement.

Save as disclosed therein, none of the Directors of the Company has any interests, direct or indirect in the above transaction, other than through their shareholding interests in the Company.

By Order of the Board
THOMSON MEDICAL GROUP LIMITED

Wilson Sam
Executive Director and Group Chief Financial Officer

05 February 2021